Biocon is currently trading at Rs. 274.65, up by 10.35 points or 3.92% from its previous closing of Rs. 264.30 on the BSE.
The scrip opened at Rs. 270.00 and has touched a high and low of Rs. 276.90 and Rs. 268.85 respectively. So far 119459 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 5 has touched a 52 week high of Rs. 341.43 on 25-Jan-2019 and a 52 week low of Rs. 211.30 on 20-Aug-2019.
Last one week high and low of the scrip stood at Rs. 276.90 and Rs. 252.70 respectively. The current market cap of the company is Rs. 31716.00 crore.
The promoters holding in the company stood at 60.67%, while Institutions and Non-Institutions held 20.76% and 18.58% respectively.
Biocon and Mylan’s supplemental Biologics License Application (sBLA) for Pegfilgrastim Drug Substance to be manufactured at Biocon’s new Biologics manufacturing facility has been approved by the US Food and Drug Administration (USFDA).
This additional approval of its new manufacturing facility for Pegfilgrastim in Bengaluru will enable Biocon Biologics, a subsidiary of Biocon, and Mylan to scale up capacity multi-fold and address the growing market opportunities in the US and other global markets. The USFDA had conducted a Pre-Approval Inspection of this new Drug Substance manufacturing facility from September 10 to September 19, 2019.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient’s worldwide.